Tetanus in Emergency Medicine Medication

  • Author: Daniel J Dire, MD, FACEP, FAAP, FAAEM; Chief Editor: Rick Kulkarni, MD   more...
 
Updated: Sep 20, 2011
 

Medication Summary

Drugs used to treat muscle spasm, rigidity, and tetanic seizures include sedative-hypnotic agents, general anesthetics, centrally acting muscle relaxants, and neuromuscular blocking agents. Antibiotics are used to prevent multiplication of C tetani, thus halting production and release of toxins.

Next

Anticonvulsants

Class Summary

Sedative-hypnotic agents are the mainstays of tetanus treatment. Benzodiazepines are the most effective primary agents for muscle spasm prevention and work by enhancing GABA inhibition. Diazepam is the most frequently studied and used drug. Diazepam reduces anxiety, produces sedation, and relaxes muscles. Lorazepam is an effective alternative. Large amounts of either may be required (up to 600 mg/d).

Phenobarbital is another anticonvulsant that may be used to prolong effects of diazepam. Phenobarbital is also used to treat severe muscle spasms and provide sedation when neuromuscular blocking agents are used.

Other agents used for spasm control include baclofen, dantrolene, short-acting barbiturates, and chlorpromazine.

Magnesium sulphate can be used alone or in combination with benzodiazepines to control spasm and autonomic dysfunction: 5 g (or 75 mg/kg) intravenous loading dose, then 2-3 g/h until spasm control is achieved.[3] Monitor patellar reflex, as areflexia (absence of patellar reflex) occurs at the upper end of the therapeutic range (4 mmol/L). If areflexia develops, dose should be decreased to avoid overdose. An infusion of magnesium sulfate does not reduce the need for mechanical ventilation in adults with severe tetanus, but it does reduce the requirement for other drugs to control muscle spasms and cardiovascular instability.[4]

Diazepam (Valium)

 

Mainstay of treatment of tetanic spasms and tetanic seizures. Depresses all levels of CNS, including limbic and reticular formation, possibly by increasing activity of GABA, a major inhibitory neurotransmitter.

Phenobarbital (Barbita, Luminal)

 

Drug dose must be small enough so that respirations are not depressed. If patient is already on a ventilator, higher doses may provide desired sedation.

Previous
Next

Skeletal muscle relaxants

Class Summary

These agents can inhibit both monosynaptic and polysynaptic reflexes at spinal level, possibly by hyperpolarization of afferent terminals.

Baclofen (Lioresal)

 

Intrathecal (IT) baclofen, a centrally acting muscle relaxant, has been used experimentally to wean patients off the ventilator and to stop diazepam infusion. IT baclofen is 600 times more potent than PO baclofen. Repeated IT injections have been efficacious in limiting duration of artificial ventilation or preventing intubation.

May induce hyperpolarization of afferent terminals and inhibit both monosynaptic and polysynaptic reflexes at spinal level.

Entire dose of baclofen is administered as a bolus injection. Dose may be repeated after 12 h or more if spontaneous paroxysms return.

Continuous IT baclofen has been reported in a very small number of patients with tetanus. Refer to manufacturer's product information on Lioresal IT for further information.

Dantrolene (Dantrium)

 

Stimulates muscle relaxation by modulating skeletal muscle contractions at a site beyond the myoneural junction and by acting directly on the muscle. Not FDA approved for use in tetanus but has been described in a small number of case reports.

Previous
Next

Antitoxins

Class Summary

These agents are used to neutralize any toxin that has not reached the CNS.

Tetanus immune globulin (TIG)

 

Used as prophylaxis against tetanus and to treat patients with circulating tetanus toxin. TIG provides passive immunity. TIG should be used to treat all patients with active tetanus, in combination with other supportive and therapeutic treatments. Should also be used to prevent tetanus in patients with inadequate or unknown immunization status after an acute injury.

Previous
Next

Antibiotics

Class Summary

Administer to patients with clinical tetanus. However, efficacy is questioned. Theoretically, antibiotics may prevent multiplication of C tetani, thus halting production of toxin. Nevertheless, a study of 364 patients found no difference in fatality rates between patients who received antibiotics and those who did not. Penicillin G is the drug of choice. Metronidazole is considered by some to be a better drug. One study demonstrated a lower mortality for patients administered metronidazole compared with penicillin.[5] Tetracycline is an alternative drug for patients who are allergic to penicillin or metronidazole. Large doses of antibiotics are recommended to favor diffusion into devitalized tissue.

Penicillin G (Pfizerpen)

 

Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.

A 10- to 14-d course of treatment is recommended. Large IV doses of penicillin may cause hemolytic anemia and neurotoxicity. Cardiac arrest has been reported in patients administered massive doses of penicillin G potassium. Patients with renal failure are particularly at risk.

Metronidazole (Flagyl)

 

Active against various anaerobic bacteria and protozoa. Appears to be absorbed into cells, and intermediate-metabolized compounds that are formed bind DNA and inhibit protein synthesis, causing cell death.

A 10- to 14-d course of treatment is recommended. Some consider this the DOC since penicillin G is also a GABA agonist, which may enhance effects of the toxin.

Doxycycline (Vibramycin, Doxychel)

 

Inhibits protein synthesis and thus bacterial growth by binding with 30S and possibly 50S ribosomal subunits of susceptible bacteria. A 10- to 14-d course of treatment is recommended.

Previous
Next

Neuromuscular blocking agents

Class Summary

These agents inhibit the transmission of nerve impulses at neuromuscular junctions of skeletal muscles and/or autonomic ganglia.

Vecuronium (Norcuron)

 

Prototypic, nondepolarizing neuromuscular blocking agent that reliably results in muscular paralysis. For maintenance of paralysis, a continuous infusion may be used.

Infants are more sensitive to neuromuscular blockade activity, and although the same dose is used, recovery is prolonged by 50%. Not recommended for use in neonates.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Daniel J Dire, MD, FACEP, FAAP, FAAEM  Clinical Professor, Department of Emergency Medicine, University of Texas Medical School at Houston; Clinical Professor, Department of Pediatrics, University of Texas Health Sciences Center San Antonio

Daniel J Dire, MD, FACEP, FAAP, FAAEM is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American College of Emergency Physicians, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Specialty Editor Board

Theodore J Gaeta, DO, MPH, FACEP  Clinical Associate Professor, Department of Emergency Medicine, Weill Cornell Medical College; Vice Chairman and Program Director of Emergency Medicine Residency Program, Department of Emergency Medicine, New York Methodist Hospital; Academic Chair, Adjunct Professor, Department of Emergency Medicine, St George's University School of Medicine

Theodore J Gaeta, DO, MPH, FACEP is a member of the following medical societies: Alliance for Clinical Education, American College of Emergency Physicians, Clerkship Directors in Emergency Medicine, Council of Emergency Medicine Residency Directors, New York Academy of Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Eddy S Lang, MDCM, CCFP(EM), CSPQ  Associate Professor, Senior Researcher, Division of Emergency Medicine, Department of Family Medicine, University of Calgary Faculty of Medicine; Assistant Professor, Department of Family Medicine, McGill University Faculty of Medicine, Canada

Eddy S Lang, MDCM, CCFP(EM), CSPQ is a member of the following medical societies: American College of Emergency Physicians, Canadian Association of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD  Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the medical review of this article by Joseph U Becker, MD.

References
  1. Pascual FB, McGinley EL, Zanardi LR, et al. Tetanus surveillance--United States, 1998--2000. MMWR Surveill Summ. Jun 20 2003;52(3):1-8. [Medline].

  2. Apte NM, Karnad DR. Short report: the spatula test: a simple bedside test to diagnose tetanus. Am J Trop Med Hyg. Oct 1995;53(4):386-7. [Medline].

  3. World Health Organization. WHO Technical Note: Current recommendations for treatment of tetanus during humanitarian emergencies. January 2010. [Full Text].

  4. Thwaites CL, Yen LM, Loan HT, Thuy TT, Thwaites GE, Stepniewska K. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. Oct 21 2006;368(9545):1436-43. [Medline].

  5. Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed). Sep 7 1985;291(6496):648-50. [Medline].

  6. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. Dec 15 2006;55(RR-17):1-37. [Medline].

  7. Hatamabadi HR, Abdalvand A, Safari S, Kariman H, Dolatabadi AA, Shahrami A, et al. Tetanus Quick Stick as an applicable and cost-effective test in assessment of immunity status. Am J Emerg Med. Sep 2011;29(7):717-20. [Medline].

  8. Bardenheier B, Prevots DR, Khetsuriani N, et al. Tetanus surveillance--United States, 1995-1997. MMWR CDC Surveill Summ. Jul 3 1998;47(2):1-13. [Medline].

  9. Checketts MR, White RJ. Avoidance of intermittent positive pressure ventilation in tetanus with dantrolene therapy. Anaesthesia. Nov 1993;48(11):969-71. [Medline].

  10. Galazka A, Gasse F. The present status of tetanus and tetanus vaccination. Curr Top Microbiol Immunol. 1995;195:31-53. [Medline].

  11. Groleau G. Tetanus. Emerg Med Clin North Am. May 1992;10(2):351-60. [Medline].

  12. Izurieta HS, Sutter RW, Strebel PM, et al. Tetanus surveillance--United States, 1991-1994. MMWR CDC Surveill Summ. Feb 21 1997;46(2):15-25. [Medline].

  13. Kefer MP. Tetanus. Am J Emerg Med. Sep 1992;10(5):445-8. [Medline].

  14. Knight AL, Richardson JP. Management of tetanus in the elderly. J Am Board Fam Pract. Jan-Feb 1992;5(1):43-9. [Medline].

  15. Murphy SM, Hegarty DM, Feighery CS, et al. Tetanus immunity in elderly people. Age Ageing. Mar 1995;24(2):99-102. [Medline].

  16. Richardson JP, Knight AL. The management and prevention of tetanus. J Emerg Med. Nov-Dec 1993;11(6):737-42. [Medline].

  17. Saissy JM, Demaziere J, Vitris M, et al. Treatment of severe tetanus by intrathecal injections of baclofen without artificial ventilation. Intensive Care Med. 1992;18(4):241-4. [Medline].

  18. Sanders RK. The management of tetanus 1996. Trop Doct. Jul 1996;26(3):107-15. [Medline].

  19. Wassilak SGF, Roper MH, Murphy TV, Orenstein WA. Tetanus. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, Pa: Saunders; 2003:745-81.

Previous
Next
 
Tetanus Cases in US from 1947-2005. From Tetanus and Tetanus Toxoid: Epidemiology and Prevention of Vaccine-Preventable Diseases. National Immunization Program, Centers for Disease Control and Prevention. January 2006.
Image from "Number of Tetanus Cases Reported and Average Annual Incidence Rates, by State." Pascual FB, McGinley EL, Zanardi LR, et al: Tetanus surveillance--United States, 1998--2000. MMWR Surveill Summ. 2003 Jun 20; 52(3): 1-8.
Image from "Number of Tetanus Cases Reported, Average Annual Incidence Rates, and Survival Status of Patients, by Age Group." Pascual FB, McGinley EL, Zanardi LR, et al: Tetanus surveillance--United States, 1998--2000. MMWR Surveill Summ. 2003 Jun 20; 52(3): 1-8.
Image from "Number of Tetanus Cases Reported Among Persons With Diabetes or Injection-Drug Use (IDU), by Age Group." Pascual FB, McGinley EL, Zanardi LR, et al: Tetanus surveillance--United States, 1998--2000. MMWR Surveill Summ. 2003 Jun 20; 52(3): 1-8.
Age Distribution of Tetanus Case in the US from 1980-2003. From Tetanus and Tetanus Toxoid: Epidemiology and Prevention of Vaccine-Preventable Diseases. National Immunization Program, Centers for Disease Control and Prevention. January 2006.
Tetanus Wound Management. From Tetanus and Tetanus Toxoid: Epidemiology and Prevention of Vaccine-Preventable Diseases. National Immunization Program, Centers for Disease Control and Prevention. January 2006.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.